Latest

3 stories

Hide weekly roundups

Wednesday, August 26

UNC registers Phase 4 trial testing Phathom's vonoprazan in Barrett's Esophagus

Trial updatePhathom Pharmaceuticals, Inc.vonoprazan

Friday, August 7

Phathom registers Phase 3 trial testing vonoprazan for episodic heartburn relief in non-erosive GERD

Trial updatePhathom Pharmaceuticals, Inc.vonoprazan

Thursday, July 30

Quarterly updatePhathom Pharmaceuticals, Inc.vonoprazan

Phathom to start Phase 3 as-needed VOQUEZNA trial in Q4 2026

Phathom reported record Q2 2026 revenue, updated full-year guidance, and set a fourth-quarter 2026 start for a new Phase 3 GERD trial plus EoE readout timing.

SEC filing